Short-acting bronchodilators
Roflumilast The specific actions of salmeterol and theophylline in the treatment of COPD have not been as well characterized as they have in asthma, but the greater improvements in physiologic and clinical outcomes observed with combination treatment are likely due to the contribution of two different pharmacologic classes
Published recommendations for cats suggest 4 mg/kg Q 8 to 12 H for nonsustained-release COPD treatment: The treatment of acute COPD with theophylline IV is not supported or recommended by current clinical practice guidelines due to significant side effects (GOLD 2019)
Combination therapy with an inhaled corticosteroid and low-dose theophylline may attenuate airway inflammation in patients with COPD
of COPD (2020 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician
Combination treatment with salmeterol plus theophylline provided significantly (p < or = 0
This study aims to evaluate the efficacy and safety of low-dose, slow-release oral theophylline administered over a 1-year period in patients with COPD
g
A Strength of recommendation: High Theophylline has an average rating of 8
7 out of 10 from a total of 14 ratings on Drugs
1 Although the use of theophylline preparations is still defined in the Global Initiative for Asthma (GINA)
Theophylline is used together with other medicines to treat the symptoms of asthma, bronchitis, emphysema, and other lung diseases